Menu
Not yet recruiting NCT07522437

The Effects of Open-label Placebos on Acute Stress

No phase Interventional Acute Stress Stress

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Open Label Placebo.
Who it may be relevant to
Registry conditions: Acute Stress, Stress. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
New Zealand
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The goal of this study is to find out whether an open-label placebo nasal spray can reduce stress among individuals engaging in a high-stress canyon swing. The main questions the study aims to answer are: 1) Does an open-label placebo increase likelihood of participants completing another jump? 2) Does the placebo affect how long it takes participants to jump, reduce the reported stress levels before the jump 3) Does the placebo change how enjoyable participants find the jump? Researchers will compare participants who receive an open-label placebo nasal spray (a spray that contains no active medication and is clearly described as a placebo) with participants who receive no treatment (control). The aim is to see whether the placebo nasal spray can increase likelihood of participants completing another jump, reduce reported stress and improve participants overall enjoyment of the jump. Participants will: * Complete a short questionnaire before they jump * Either self administer a placebo nasal spray (one spray in each nostril) right before stepping through the gate to jump, or receive no treatment (control). * Complete a short questionnaire after completing the jump * Whether they complete another jump will be noted

Detailed description

This randomised controlled trial evaluates whether an open label placebo can increase likelihood of participants completing another jump and reduce stress among individuals engaging in a high-stress canyon swing. The intervention is based on prior research on placebo effects - which suggest that expectations and prior learning can produce meaningful physiological and psychological responses to a treatment - even when individuals are aware they are receiving a placebo, known as an open-label placebo. Open-label placebos challenge traditional assumptions by offering an ethically acceptable way to harness the mechanisms of placebos without deception. Prior research shows that open-label placebos can improve a range of self-reported outcomes including reducing stress, pain, and anxiety.

The study examines the effects of an open-label placebo on stress in a real world setting. The primary objective is to assess whether an open-label placebo nasal spray can increase likelihood of participants completing another jump. Secondary objectives include examining whether the placebo influences reported stress time taken to jump, and ratings of the jump in terms of enjoyment.

Participants who have signed up to complete the Shotover Canyon Swing Queenstown and meet the eligibility criteria are randomly assigned in a 1:1 ratio to one of two study arms; either an open-label placebo group or no-treatment control group. Randomisation is conducted independently using a computer-generated allocation sequence. Participants in the placebo group will self-administer the nasal spray once in each nostril immediately prior to stepping through the gate to jump. The nasal spray is made of a saline solution and is explicitly described as a placebo with no active ingredients. Participants in the control group receive no intervention and continue as normal. Statistical analyses will include independent samples t-tests to compare mean differences in primary and secondary outcomes between groups. Missing data will be addressed using multiple imputation techniques. All eligibility criteria, outcome measures and intervention details are specified in the relevant sections of the clinical trial registration record. This trial contributes to a growing body of research examining the effects of open-label placebos and explores whether these mechanisms extends the research into naturalistic, non-clinical settings.

Interventions

  • Other Open Label Placebo
    Participants allocated to the placebo arm will self-administer the nasal spray before entering through the gate to jump. The nasal spray contains no active ingredients. It is made of a saline solution and is described to participants as a placebo. Participants are informed that placebos can produce powerful effects and have been shown to reduce stress and anxiety through expectations and prior learning - processes where the body learns to respond automatically to cues that are associated with a

Primary outcome measures

  • Repeat jump [Time frame: During the same study session, immediately following completion of the participant's initial jump.]
Secondary outcome measures (4)
  • Self reported stress [Time frame: Answered at baseline on the pre-jump questionnaire and immediately after completion of the jump on the post-jump questionnaire, during the same study session.]
  • Time to jump [Time frame: During the study session. Time is recorded in seconds. The recording starts when the participant is clipped onto the main attachment point rigging plate and stops recording when they leave the jump platform and drop into the canyon.]
  • Enjoyment of the jump [Time frame: Answered immediately after completion of the jump on the post jump questionnaire, during the same study session.]
  • Willingness to jump again [Time frame: Answered immediately after completion of the jump on the post jump questionnaire, during the same study session.]

Eligibility criteria

Inclusion criteria

  • Signed-up to complete the canyon swing
  • Aged 18 years and over
  • Able to speak and understand English
  • Comfortable being randomised to either the open-label placebo or no-treatment control condition

Exclusion criteria

  • Under 18 years of age
  • Unable to speak or understand English
  • Unable to provide informed consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

New Zealand · 1 center
  • Canyon Swing — Queenstown

Identifiers

NCT: NCT07522437 · UAHPEC30520

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗